MaxCyte, Inc. Exercise of options and PDMR Dealing (7413S)
November 17 2021 - 12:36PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7413S
MaxCyte, Inc.
17 November 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options, PDMR dealing and Total Voting Rights
Gaithersburg, Maryland, November 17, 2021 - MaxCyte, Inc.,
(NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial
cell-engineering company focused on providing enabling platform
technologies to advance innovative cell-based research as well as
next-generation cell therapeutic discovery, development and
commercialization, announces that Doug Doerfler, Chief Executive
Officer and Founder of the Company and Amanda Murphy, Chief
Financial Officer, have exercised options over 350,000 shares of
common stock of $0.01 of the Company ("Common Stock") ("Exercise")
in aggregate. The 350,000 new shares of Common Stock issued
pursuant to the Exercise ("New Common Stock"), together with
100,000 shares previously owned by Doug Doerfler, have been sold by
Doug Doerfler and Amanda Murphy at a price range between of $12.08
and $12.66 per Common Stock ("Sale"). The sold shares represent
approximately 10% and 12% of Doug Doerfler's and Amanda Murphy
total equity and option holdings in the Company's stock capital,
respectively.
Following the Exercise and Sale, Doug Doerfler holds 333,197
shares of Common Stock representing 0.3% of the issued stock
capital of the Company and Amanda Murphy holds 0 shares of Common
Stock. Following the Exercise, Doug Doerfler and Amanda Murphy hold
a further 2,516,680 and 1,065,470 options over Common Stock
respectively.
Total voting rights
The 350,000 New Common Stock have been admitted to trading on
AIM pursuant to the Block Listing announced by the Company on
September 6, 2021. The New Common Stock will rank pari passu with
the existing shares of common stock of the Company and will trade
in the unrestricted line of Common Stock trading under the symbol
MXCT. The total issued stock capital of the Company following the
above will be 101,168,137 shares of common stock. Shareholders in
the Company may use this figure as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
stock capital of the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 100,838,137 and the number of restricted
shares of Common Stock trading under the symbol 'MXCL' is
330,000.
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: three instruments, the ATx(TM), STx(TM) and
GTx(TM); a portfolio of proprietary related processing assemblies
or disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and/or persons closely
associated with them:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name a) Doug Doerfler
b) Amanda Murphy
------------------------------------------------------------ -------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------------------------
a) Chief Executive Officer
a) Position/status b) Chief Financial Officer
------------------------------------------------------------ -------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------------ -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------------------------
a) Name MaxCyte, Inc.
------------------------------------------------------------ -------------------------------------------
b) LEI 54930053YHXULRFCU991
------------------------------------------------------------ -------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
---------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument $0.01 ordinary shares
Identification code
US57777K1060
------------------------------------------------------------ -------------------------------------------
b) Nature of the transaction Exercise of options over Common Stock
------------------------------------------------------------ -------------------------------------------
c) Price(s) and volume(s) Price(s) per Ordinary Volume(s)
Share
a) N/A a) 200,000
b) N/A b) 150,000
---------------------- -----------------
------------------------------------------------------------ -------------------------------------------
d) Aggregated information:
* Aggregated volume: 350,000
N/A
-- Price:
------------------------------------------------------------ -------------------------------------------
e) Date of the transaction 12 to 16 November 2021
------------------------------------------------------------ -------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------------ -------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name a) Doug Doerfler
b) Amanda Murphy
------------------------------------------------------------- -------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------
a) Chief Executive Officer
a) Position/status b) Chief Financial Officer
------------------------------------------------------------- -------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------------------------
a) Name MaxCyte, Inc.
------------------------------------------------------------- -------------------------------------------
b) LEI 54930053YHXULRFCU991
------------------------------------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument $0.01 ordinary shares
Identification code
US57777K1060
------------------------------------------------------------- -------------------------------------------
b) Nature of the transaction Sale of Common Stock
------------------------------------------------------------- -------------------------------------------
c) Price(s) and volume(s) Price(s) per Ordinary Volume(s)
Share
a) $12.6573 a) 101,847
a) $12.1600 a) 123,263
a) $12.0769 a) 74,890
b) $12.6572 b) 51,103
b) $12.1605 b) 61,591
b) $12.0769 b) 37,306
---------------------- -----------------
------------------------------------------------------------- -------------------------------------------
d) Aggregated information:
* Aggregated volume: 450,000
$12.2981
-- Price:
------------------------------------------------------------------- -------------------------------------------
e) Date of the transaction 12 to 16 November 2021
------------------------------------------------------------- -------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXFXFDLFFFA
(END) Dow Jones Newswires
November 17, 2021 12:36 ET (17:36 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
